Comparative Efficacy of Four Treatments in Patients with Graves’ Disease: a Network Meta-analysis

Abstract

Background: The question of which treatment should be preferred for the treatment of Graves’ disease is debatable, and pairwise meta-analyses could not obtain hierarchies of these treatments. Our intention was to integrate the evidence to provide hierarchies of the comparative efficacy of 4 treatments (radioiodine, radioiodine+prednisone, antithyroid drugs and surgery).

Methods: We conducted a Bayesian-framework network meta-analysis of randomized controlled trials (RCTs) to compare 4 treatments in patients with Graves’ disease. The eligible RCTs were identified by searching Amed, the British Nursing Index, Embase, PubMed, the Cochrane Central Register of Controlled Trials (CENTRAL), Google scholar, SIGLE, the National Technical Information Service, the National Research Register (UK) and the Current Controlled Trials databases. The data for 2 outcomes (e. g., ophthalmopathy and recurrence) were independently extracted by 2 authors.

Results: A total of 4 RCTs were ultimately included. Radioiodine+prednisone therapy showed statistical significance in reducing the incidence of new or deteriorative ophthalmopathy comparing with the other 3 therapies. Compared with radioiodine, therapy with antithyroid drugs therapy as well as surgery significantly decreased the incidence of new or deteriorative ophthalmopathy. Radioiodine therapy significantly reduced the rate of recurrence when compared to therapy with antithyroid drugs or surgery. For decreasing the incidence of new or deteriorative ophthalmopathy, the 4 treatments were ranked as follows: radioiodine+prednisone therapy, therapy with antithyroid drugs, surgery and radioiodine therapy. For reducing the rate of recurrence, 3 treatments were ranked as follows: radioiodine therapy, therapy with antithyroid drugs and surgery.

Conclusions: Radioiodine+prednisone therapy might have the least probability of leading to an exacerbation or new appearance of ophthalmopathy, and radioiodine therapy might have the least probability of causing a recurrence.

Key words

Graves’ disease - network - RCTs - ophthalmopathy - recurrence

• References

• 1 Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmunity reviews 2003; 2: 119-125
• 2 Abraham-Nordling M, Bystrom K, Torring O et al. Incidence of hyperthyroidism in Sweden. European journal of endocrinology/European Federation of Endocrine Societies 2011; 165: 899-905
• 3 Menconi F, Marcocci C, Marino M. Diagnosis and classification of Graves’ disease. Autoimmunity reviews 2014; 13: 398-402
• 4 Weetman AP. Graves’ disease. The New England journal of medicine 2000; 343: 1236-1248
• 5 Lai A, Sassi L, Compri E et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves’ orbitopathy: a retrospective cohort study. The Journal of clinical endocrinology and metabolism 2010; 95: 1333-1337
• 6 Fehlings MG, Theodore N, Harrop J et al. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. Journal of neurotrauma 2011; 28: 787-796
• 7 Bartalena L, Marcocci C, Bogazzi F et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. The New England journal of medicine 1998; 338: 73-78
• 8 Chen DY, Jing J, Schneider PF et al. Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hyperthyroidism. Nuclear medicine communications 2009; 30: 160-168
• 9 Tallstedt L, Lundell G, Torring O et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. The New England journal of medicine 1992; 326: 1733-1738
• 10 Traisk F, Tallstedt L, Abraham-Nordling M et al. Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. The Journal of clinical endocrinology and metabolism 2009; 94: 3700-3707
• 11 Alizadeh J, Ward JA. Comparative follow-up of patients with hyperthyroidism treated with 131 or surgery. Journal of the Medical Association of Georgia 1979; 68: 101-104
• 12 Berglund J, Christensen SB, Dymling JF et al. The incidence of recurrence and hypothyroidism following treatment with antithyroid drugs, surgery or radioiodine in all patients with thyrotoxicosis in Malmo during the period 1970–1974. Journal of internal medicine 1991; 229: 435-442
• 13 Leary AC, Grealy G, Higgins TM et al. Long-term outcomes of treatment of hyperthyroidism in Ireland. Irish journal of medical science 1999; 168: 47-52
• 14 Pineda G, Arancibia P, Mejia G. Treatment of Basedow-Graves’ hyperthyroidism: retrospective analysis after 30 years. Revista medica de Chile 1998; 126: 953-962
• 15 Sugrue D, McEvoy M, Feely J et al. Hyperthyroidism in the land of Graves: results of treatment by surgery, radio-iodine and carbimazole in 837 cases. The Quarterly journal of medicine 1980; 49: 51-61
• 16 Abraham-Nordling M, Wallin G, Traisk F et al. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. European journal of endocrinology/European Federation of Endocrine Societies 2010; 163: 651-657
• 17 Mengistu M. A prospective study of 110 Ethiopians with thyrotoxicosis. East African medical journal 1992; 69: 515-519
• 18 Torring O, Tallstedt L, Wallin G et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine – a prospective, randomized study. Thyroid Study Group. The Journal of clinical endocrinology and metabolism 1996; 81: 2986-2993
• 19 Tutuncu NB, Tutuncu T, Ozgen A et al. Long-term outcome of Graves’ disease patients treated in a region with iodine deficiency: relapse rate increases in years with thionamides. Journal of the National Medical Association 2006; 98: 926-930
• 20 Sundaresh V, Brito JP, Wang Z et al. Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. The Journal of clinical endocrinology and metabolism 2013; 98: 3671-3677